Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 14/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | CCND1 | P24385 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.44 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10346322 | 0.77 | BRD4 (0.53) | ALKBRD4CDK1CDK4CCND1 | |
| SCHEMBL10192608 | 0.77 | HTR1A (0.34) | — | |
| SCHEMBL660300 | 0.77 | CDK4 (0.66) | ALKCDK1CDK4CCND1CDK2 | |
| SCHEMBL10192606 | 0.75 | HTR1A (0.33) | — | |
| SCHEMBL15035264 | 0.75 | CDK4 (0.51) | ALKBRD4CDK1CDK4CCND1 | |
| SCHEMBL15035284 | 0.75 | CDK4 (0.51) | ALKBRD4CDK1CDK4CCND1 | |
| SCHEMBL15035271 | 0.74 | CDK4 (0.50) | ALKBRD4CDK1CDK4CCND1 | |
| SCHEMBL15035278 | 0.74 | CDK4 (0.50) | ALKBRD4CDK4CCND1CDK2 | |
| SCHEMBL26061435 | 0.70 | ALK (0.64) | ALKBRD4CDK1CDK4CCND1 | |
| SCHEMBL15035280 | 0.70 | TNK2 (0.52) | ALKBRD4CDK1CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | ALK 3635/4885BRD4 248/4885CDK1 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.